Expectations rise for Rinvoq in treating severe AD

By | translator Alice Kang

21.11.09 13:04:49

가나다라 0

Unlike ‘Dupixent,’ which targets key cytokines, Rinvoq provides more broader involvement

Is recognized for catching ‘both birds with one stone,’ with its immediate effect and convenience in administration

“Shows large symptom improvement even when switching from Dupixent→Rinvoq… the drug’s long-term effect remains to be seen.”

A second JAK inhibitor has been introduced to the field of moderate-to-severe atopic dermatitis treatment. Abbvie’s ‘Rinvoq (upadacitinib),’ with its double advantage in improved convenience and effect, is heralding new change in the field of AD treatment.

Rinvoq was additionally approved for the atopic dermatitis indication on the 6th last month by the Ministry of Food and Drug Safety. With the approval, Rinvoq is now approved for patients with moderate-to-severe atopic dermatitis in adults and adolescents over the age of 12.

Rinvoq became the second JAK inhibitor after ‘Olumiant’ to be approved for atopic dermatitis. Also, the addition of Rinvoq increased the number of options for

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)